{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.1","upperLimit":"14.9","value":"7.23"},{"groupId":"OG001","lowerLimit":"1.2","upperLimit":"23.1","value":"9.26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Time to CR or better was defined as the time from randomization until onset of first CR or better.","dispersionType":"Full Range","groups":[{"description":"Participants received daratumumab intravenous infusion (Dara IV) 16 milligrams per kilogram (mg/kg) once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease progression, unacceptable toxicity, withdrawal of consent, the investigator decides to stop treatment, or the start of subsequent anticancer therapy. The duration for each cycle was 28 days.","id":"OG000","title":"Daratumumab IV"},{"description":"Participants received daratumumab 1800 mg subcutaneous injection (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Units per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease progression, unacceptable toxicity, withdrawal of consent, the investigator decides to stop treatment, or the start of subsequent anticancer therapy. The duration for each cycle was 28 days.","id":"OG001","title":"Daratumumab SC"}],"paramType":"MEDIAN","populationDescription":"Participants analyzed included responders (CR or better) in ITT analysis set. Here, 'N' (number of participants analysed) signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Time to Complete Response (CR) or Better","type":"SECONDARY","unitOfMeasure":"months"}